CAVA Group Inc vs IDEXX Laboratories, Inc. — how do they compare? CAVA Group Inc trades at $69.68 (market cap $7.08B), while IDEXX Laboratories, Inc. trades at $573.62 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× CAVA Group Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CAVA | IDXX | |
|---|---|---|
Market Cap | $7.08B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $766.68 |
52-Week Low | $43.59 | $526.44 |
Enterprise Value | $7.23B | $47.12B |
Signals from Pluang's Aura AI — not financial advice
CAVA stock surged 12.32% to $69.165, driven by strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. Despite a bearish technical signal, fundamentals show robust expansion with same-store sales up 9% and net income margin at 4.79%. Analyst consensus remains strongly bullish with a $89.75 price target, though high valuations like a P/E of 108.59 pose concerns.
Outlook is positive due to earnings momentum and market share gains, but risks include valuation sensitivity and competitive pressures. Investors should weigh growth potential against premium multiples, with institutional support underscoring long-term confidence amid near-term volatility.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →